A detailed history of Northern Trust Corp transactions in Immuneering Corp stock. As of the latest transaction made, Northern Trust Corp holds 39,729 shares of IMRX stock, worth $89,390. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,729
Previous 158,917 75.0%
Holding current value
$89,390
Previous $203,000 51.72%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.03 - $3.21 $122,763 - $382,593
-119,188 Reduced 75.0%
39,729 $98,000
Q2 2024

Aug 14, 2024

SELL
$1.28 - $2.75 $21,872 - $46,992
-17,088 Reduced 9.71%
158,917 $203,000
Q1 2024

May 14, 2024

SELL
$1.91 - $7.32 $15,131 - $57,989
-7,922 Reduced 4.31%
176,005 $508,000
Q4 2023

Feb 13, 2024

SELL
$4.84 - $8.44 $7,410 - $12,921
-1,531 Reduced 0.83%
183,927 $1.35 Million
Q3 2023

Nov 13, 2023

BUY
$7.21 - $10.68 $88,228 - $130,691
12,237 Added 7.06%
185,458 $1.42 Million
Q2 2023

Aug 11, 2023

BUY
$6.49 - $13.36 $882,127 - $1.82 Million
135,921 Added 364.4%
173,221 $1.76 Million
Q1 2023

May 15, 2023

BUY
$3.78 - $10.38 $9,979 - $27,403
2,640 Added 7.62%
37,300 $362,000
Q3 2022

Nov 14, 2022

BUY
$5.0 - $14.32 $94,885 - $271,750
18,977 Added 121.0%
34,660 $496,000
Q2 2022

Aug 12, 2022

SELL
$3.89 - $7.81 $497,433 - $998,703
-127,875 Reduced 89.08%
15,683 $85,000
Q1 2022

May 13, 2022

BUY
$6.47 - $16.99 $437,805 - $1.15 Million
67,667 Added 89.16%
143,558 $929,000
Q4 2021

Feb 08, 2022

BUY
$16.12 - $31.02 $52,857 - $101,714
3,279 Added 4.52%
75,891 $1.23 Million
Q3 2021

Nov 15, 2021

BUY
$17.0 - $32.84 $1.23 Million - $2.38 Million
72,612 New
72,612 $1.93 Million

Others Institutions Holding IMRX

About Immuneering Corp


  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $59.4M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.